Japan · Delayed Price · Currency is JPY Mitsubishi Chemical Group Earnings Call Transcripts
Fiscal Year 2026
-
FY 2025 results were heavily impacted by non-recurring losses and structural reforms, leading to a sharp decline in profits. However, significant growth is forecast for FY 2026, driven by Specialty Materials and ongoing cost reductions, with risks from Middle East tensions closely monitored.
-
Q3 FY25 saw steady semiconductor-related business but weak materials demand, with net income up 77% year-on-year due to asset sales. Full-year profit forecast was cut sharply on non-recurring losses from business exits, while core operating income guidance is maintained.
-
Core operating income exceeded forecasts, but revenue and profit declined year-on-year due to MMA market weakness and restructuring costs. Specialty materials and industrial gases performed well, while asset sales and cost reductions improved cash flow and financial ratios.
-
Q1 FY2025 saw lower revenue and profit due to weak markets and restructuring, but specialty materials and semiconductor segments outperformed expectations. Cost reductions and asset sales supported cash flow, while full-year and dividend guidance remain unchanged.
Fiscal Year 2025
-
Core operating income rebounded strongly, but net income fell due to structural reform costs. FY2025 guidance anticipates higher profits, supported by portfolio transformation, share buybacks, and growth investments funded by the Mitsubishi Tanabe Pharma transfer.
-
Q3 FY2024 saw 3% revenue and 34% core operating income growth year-on-year, with strong performance in Specialty Materials and MMA, but net income fell due to special losses. Q4 is expected to be weaker across most segments, but full-year forecasts and dividend guidance remain unchanged.
-
First half FY24 results surpassed forecasts with strong MMA and display demand, but net income fell due to restructuring costs. Full-year core operating income guidance was raised, though second half performance is expected to soften amid weaker display and semiconductor demand.
-
Q1 FY2024 delivered strong sales and core operating income growth, driven by robust display, semiconductor, and pharma segments, while Carbon Products continued to post losses. Structural reforms and capacity reductions are underway, with full-year guidance maintained.